SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT2), EXPRESSED IN THE PROXIMAL RENAL TUBULES, IS RESPONSIBLE FOR THE MAJORITY OF THE REABSORPTION OF FILTERED GLUCOSE FROM THE TUBULAR LUMEN. CANAGLIFLOZIN, AN INHIBITOR OF SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT2), REDUCES REABSORPTION OF FILTERED GLUCOSE AND LOWERS THE RENAL THRESHOLD FOR GLUCOSE (RTG), AND THEREBY INCREASES URINARY GLUCOSE EXCRETION.